Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis.
We describe a 60-year-old woman with active rheumatoid arthritis (RA) and endstage renal disease secondary to hypertensive nephrosclerosis undergoing hemodialysis. She had tried multiple antirheumatic medications; however, their usefulness was limited due to toxic side effects or lack of efficacy. She was then treated with chimeric antitumor necrosis factor monoclonal antibody (infliximab), which resulted in immediate improvement in clinical and laboratory measures. After about 2 years of therapy, no side effects have been observed. This report expands the spectrum of infliximab to include RA patients with renal insufficiency.
Singh
Ranju
R
Department of Medicine, Louisiana State University Health Science Center at New Orleans, 70112-2822, USA.
Cuchacovich
Raquel
R
Huang
Wenqun
W
Espinoza
Luis R
LR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D006435:Renal Dialysis
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab